Abeona Therapeutics - ABEO Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings or view top-rated stocks.

2 analysts have issued 1-year price objectives for Abeona Therapeutics' stock. Their ABEO share price forecasts range from $40.00 to $40.00. On average, they expect the company's share price to reach $40.00 in the next year. This suggests a possible upside of 1,573.6% from the stock's current price.
View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts.

Abeona Therapeutics' stock was trading at $3.08 at the start of the year. Since then, ABEO stock has decreased by 22.4% and is now trading at $2.39.
View the best growth stocks for 2023 here.

Abeona Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 460,500 shares, an increase of 6.7% from the February 13th total of 431,600 shares. Based on an average daily volume of 244,900 shares, the short-interest ratio is presently 1.9 days. Currently, 2.8% of the company's shares are short sold.
View Abeona Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ABEO earnings forecast.

Abeona Therapeutics Inc (NASDAQ:ABEO) issued its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($4.00).

Abeona Therapeutics shares reverse split on the morning of Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Abeona Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (6.70%), Armistice Capital LLC (6.44%), EcoR1 Capital LLC (6.33%), AIGH Capital Management LLC (3.80%), Nantahala Capital Management LLC (1.59%) and Barclays PLC (1.08%). Insiders that own company stock include Brendan M O'malley, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc and Todd Wider.
View institutional ownership trends.

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABEO stock can currently be purchased for approximately $2.39.

Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $41.06 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-84,940,000.00 in net income (profit) each year or ($18.31) on an earnings per share basis.

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101.